According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside ...

Boehringer drug scores in another pulmonary fibrosis trial Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

Latest medical research on lung disease. Learn about the symptoms of chronic obstructive pulmonary disease (COPD), emphysema, and lung cancer along with the latest treatment information.

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

A research team led by Prof. LI Hai from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, has developed a new model that can accurately predict lung motion caused by ...